20-deoxy-23-deoxy-20-[N-methyl-N-(1-(3-quinolyl)-1H-1,2,3-triazol-4-yl]methylamino)-23-(piperidine-1-yl)-5-O-mycaminosyltylonolide

ID: ALA5169799

Chembl Id: CHEMBL5169799

PubChem CID: 86291473

Max Phase: Preclinical

Molecular Formula: C49H73N7O8

Molecular Weight: 888.16

Names and Identifiers

Canonical SMILES:  CC[C@H]1OC(=O)C[C@@H](O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](N(C)C)[C@H]2O)[C@@H](CCN(C)Cc2cn(-c3cnc4ccccc4c3)nn2)C[C@@H](C)C(=O)/C=C/C(C)=C/[C@@H]1CN1CCCCC1

Standard InChI:  InChI=1S/C49H73N7O8/c1-9-43-37(28-55-20-13-10-14-21-55)23-31(2)17-18-41(57)32(3)24-36(19-22-54(8)29-38-30-56(52-51-38)39-25-35-15-11-12-16-40(35)50-27-39)48(33(4)42(58)26-44(59)63-43)64-49-47(61)45(53(6)7)46(60)34(5)62-49/h11-12,15-18,23,25,27,30,32-34,36-37,42-43,45-49,58,60-61H,9-10,13-14,19-22,24,26,28-29H2,1-8H3/b18-17+,31-23+/t32-,33+,34-,36+,37-,42-,43-,45+,46-,47-,48-,49+/m1/s1

Standard InChI Key:  UPEHOGVLCWTGAR-NLCGWVTRSA-N

Alternative Forms

1. Parent:

   

   ALA5169799

   (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-[2-[methyl-[(1-quinolin-3-yltriazol-4-yl)methyl]amino]ethyl]-15-(piperidin-1-ylmethyl)-1-oxacyclohexadeca-11,1

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 888.16

Molecular Weight (Monoisotopic): 887.5521

AlogP: 4.96

#Rotatable Bonds: 12

Polar Surface Area: 175.84

Molecular Species: BASE

HBA: 15

HBD: 3

#RO5 Violations: 2

HBA (Lipinski): 15

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 12.68

CX Basic pKa: 9.28

CX LogP: 5.27

CX LogD: 2.70

Aromatic Rings: 3

Heavy Atoms: 64

QED Weighted: 0.21

Np Likeness Score: 0.37

References

1. Zhai H, Luo C, Yang P, Zhang S, Wang H, Cao Y, Yang Y, Liu H, Kong X, Arhema Frejat FO, Ren C, Shi X, Wu C..  (2022)  Design, synthesis and activity against drug-resistant bacteria evaluation of C-20, C-23 modified 5-O-mycaminosyltylonolide derivatives.,  238  [PMID:35675753] [10.1016/j.ejmech.2022.114495]

Source

Source(1):

• Scientific Literature